Login / Signup

Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I/IIa Study.

Zhenlei WangXinghai LiYing JinRunhan LiuXiangjie DiYi ZhouYing WangLei FanYuanwei ChenYongsheng WangLi Zheng
Published in: The Journal of clinical endocrinology and metabolism (2022)
HP501 was effective at reducing sUA in healthy volunteers and hyperuricemic patients with a tolerable safety profile, warranting further development.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • uric acid
  • prognostic factors
  • patient reported outcomes
  • metabolic syndrome
  • patient reported